Broadly reactive antibodies targeting the conserved hemagglutinin (HA) stalk region are elicited following sequential infection or vaccination with influenza viruses belonging to divergent subtypes and/or expressing antigenically distinct HA globular head domains. Here, we demonstrate, through the use of novel chimeric HA proteins and competitive binding assays, that sequential infection of ferrets with antigenically distinct seasonal H1N1 (sH1N1) influenza virus isolates induced an HA stalk-specific antibody response. Additionally, stalk-specific antibody titers were boosted following sequential infection with antigenically distinct sH1N1 isolates in spite of preexisting, cross-reactive, HA-specific antibody titers. Despite a decline in stalk-specific serum antibody titers, sequential sH1N1 influenza virus-infected ferrets were protected from challenge with a novel H1N1 influenza virus (A/California/07/2009), and these ferrets poorly transmitted the virus to naive contacts. Collectively, these findings indicate that HA stalk-specific antibodies are commonly elicited in ferrets following sequential infection with antigenically distinct sH1N1 influenza virus isolates lacking HA receptor-binding site cross-reactivity and can protect ferrets against a pathogenic novel H1N1 virus.
IMPORTANCE
The influenza virus hemagglutinin (HA) is a major target of the humoral immune response following infection and
The influenza virus is highly contagious and causes an acute respiratory illness, with seasonal epidemics in the human population. Despite global vaccination efforts, influenza remains a major medical issue and is responsible for substantial morbidity and mortality annually. It is estimated that 5 to 20% of the people in the United States contract influenza virus annually, and more than 200,000 people require hospitalization due to influenza-related complications (according to the Centers for Disease Control and Prevention, Atlanta, GA [http://www.cdc.gov/flu/about/qa /disease.htm; accessed 1 September 2015]). The young, the elderly, pregnant females, and those with certain medical conditions are at an increased risk for influenza-associated complications.Current vaccination approaches primarily rely on the induction of antibodies recognizing hemagglutinin (HA) (1). The HA glycoprotein is expressed as a trimeric complex of identical subunits on the surface of influenza virus virions. HA mediates virus attachment and subsequent membrane fusion with target cells (2, 3). Individual HA monomers can be further segregated into the membrane-distal globular head and membrane-proximal stalk domains. The globular head encodes the receptor-binding site (RBS), and the stalk domain encodes the fusion peptide (2).Antibodies directed against HA and, more specifically, to epitopes in close proximity to the RBS within the globular head region are elicited following infection or vaccination (4). These antibodies possess a potent neutralization capacity through the ability to interfere with viral attachment to target cells and a...